After more than a century of pursuing cancer through direct assault—cutting, burning, and poisoning—medicine stands at a transformative moment. The convergence of checkpoint inhibitor immunotherapy with techniques that induce immunogenic cell death (ICD) represents a fundamental shift in cancer treatment philosophy. Rather than attempting to destroy every cancer cell directly, this approach harnesses the body's immune system to recognize and eliminate cancer throughout the body, including circulating cancer stem cells that have long undermined conventional treatments.
Leading this revolution are pioneering researchers and clinicians who have recognized that cancer cure requires comprehensive immune system restoration. From Ian Zagon's groundbreaking work at Penn State on immune enhancement protocols, to the father-son team of Arthur and Burton Berkson successfully treating advanced cancers with low-cost supplements and repurposed medicines, to Patrick Soon-Shiong's ImmunityBio achieving FDA expanded access for Anktiva—we are witnessing the emergence of non-toxic cancer treatments that address root causes rather than symptoms.
Critically, these pioneers recognize that treating underlying viral infections—both active and latent—is essential for cancer cure. When viruses occupy the immune system, cancer cells escape detection and destruction. This white paper traces the historical development of cancer immunotherapy and examines why the combination of immune restoration, viral suppression, and ICD-inducing modalities represents humanity's best chance to make cancer history.
For over a century, cancer treatment has relied on three pillars: surgery, radiation, and chemotherapy. While these modalities have extended lives, they share a fundamental limitation—they target only the tumors we can see or detect. This approach has consistently failed to address the root causes of cancer mortality: metastatic disease driven by circulating cancer stem cells (CSCs) and the underlying immune dysfunction that allowed cancer to develop initially.
The persistence of CSCs explains why cancer recurrence rates remain stubbornly high across most cancer types. A patient may achieve complete radiographic response, only to suffer recurrence months or years later from cancer cells that survived in circulation or distant sites. Modern oncology's failure to adequately address both CSCs and immune dysfunction has created a therapeutic ceiling that conventional approaches cannot breach.
Dr. Patrick Soon-Shiong of ImmunityBio was among the first to recognize critical patterns: most cancer patients have abnormally low absolute lymphocyte counts, and many harbor chronic viral infections that further compromise immunity. These observations—that cancer represents as much an immune deficiency disease as a cellular proliferation disorder—would prove pivotal in developing new therapeutic approaches.
The story of cancer immunotherapy begins in the 1890s with William Coley, a New York surgeon who made a remarkable observation. Patients who developed post-operative bacterial infections sometimes experienced spontaneous tumor regression. This led him to deliberately inject streptococcal organisms into tumors, achieving complete remissions in approximately 10% of cases—rates that rival many modern therapies.
Coley's work represented the first systematic attempt to harness immunogenic cell death. The bacterial infections triggered massive inflammatory responses that not only destroyed local tumor cells but also generated systemic immunity against cancer. His approach worked because it addressed what we now understand as fundamental requirements for cancer cure: systemic immune activation capable of eliminating both visible tumors and circulating cancer stem cells.
Over a decade ago, research scientist Ian Zagon at Penn State University developed a groundbreaking protocol for immune system enhancement that would revolutionize integrative cancer treatment. Zagon's work focused on the opioid growth factor (OGF) system and its role in immune regulation and cell proliferation. His research demonstrated that low-dose naltrexone (LDN) could profoundly modulate immune function by:
Zagon's protocol represented a paradigm shift: rather than attacking cancer directly, it restored the body's natural ability to recognize and eliminate malignant cells. This work laid the foundation for a new generation of clinicians who would combine immune enhancement with other integrative approaches.
At the Integrative Medical Center of New Mexico, Dr. Arthur Berkson and his son Dr. Burton Berkson have spent decades refining and clinically validating Zagon's insights. Their work represents perhaps the most comprehensive real-world application of immune enhancement protocols combined with targeted nutritional interventions.
The Berksons' approach centers on what they term the "ALA/N Protocol"—combining alpha-lipoic acid with low-dose naltrexone. Their published studies document remarkable results:
Pancreatic Cancer Success: In their paper "Revisiting the ALA/N (α-Lipoic Acid/Low-Dose Naltrexone) Protocol for People With Metastatic and Nonmetastatic Pancreatic Cancer: A Report of 3 New Cases," the Berksons documented long-term survival in patients with one of medicine's most lethal cancers. Patients who would typically survive months lived years with good quality of life.
Stage IV Renal Cell Carcinoma: Their case report "The Long-Term Survival of a Patient With Stage IV Renal Cell Carcinoma Following an Integrative Treatment Approach Including the Intravenous α-Lipoic Acid/Low-Dose Naltrexone Protocol" described a patient who achieved durable remission of metastatic kidney cancer—a result rarely seen with conventional treatment.
The Berksons' protocol works through multiple synergistic mechanisms:
The Berksons' work extends beyond cancer to chronic viral infections, recognizing the intimate connection between viral burden and cancer development. Their paper "A conservative triple antioxidant approach to the treatment of hepatitis C" and "Combination of alpha lipoic acid (thioctic acid), silymarin, and selenium: three case histories" demonstrated successful treatment of hepatitis C using only supplements—avoiding the toxic and expensive conventional antivirals.
This work proved prophetic. We now understand that chronic viral infections:
In 1953, R.H. Mole coined the term "abscopal effect" to describe the mysterious phenomenon where local radiation caused regression of distant, untreated tumors. For decades, this remained a curiosity—occurring in less than 1% of patients receiving radiation alone. Recent research has revealed why: the key to achieving abscopal effects lies in minimal radiation exposure combined with immune stimulation.
Studies now demonstrate that the abscopal effect is most likely with just one or two radiation treatments when combined with immunotherapy. This finding should have revolutionized radiation oncology, yet implementation remains rare. The reason is primarily financial: radiation oncology departments have invested millions in equipment and built business models around delivering 30-40 treatments per patient. A patient receiving two treatments generates perhaps 5% of the revenue of traditional fractionated courses.
This financial conflict has tragic consequences. Extended radiation courses:
The evidence suggests radiation therapy, as currently practiced, actively prevents cancer cure by suppressing the immune response necessary for eliminating circulating cancer stem cells. Forward-thinking oncologists increasingly recognize that radiation's future role will be minimal—perhaps limited to single-fraction treatments in combination protocols, before being replaced entirely by immune-preserving alternatives like histotripsy.
The development of checkpoint inhibitors represents the most significant advance in cancer treatment since chemotherapy. By blocking proteins like CTLA-4, PD-1, and PD-L1, these drugs remove the "brakes" that tumors use to evade immune destruction. However, checkpoint inhibitors alone face critical limitations—they can only unleash responses against cancers the immune system has already recognized.
This is where the work of pioneers like the Berksons becomes crucial. Their protocols don't just remove immune brakes; they restore fundamental immune competence through:
When combined with checkpoint inhibitors, these metabolic interventions dramatically improve response rates by ensuring a competent immune system exists to be unleashed.
The rehabilitation of chemotherapy from poison to immunomodulator represents one of oncology's most important paradigm shifts. Low-dose metronomic chemotherapy—continuous administration of conventional chemotherapeutic agents at doses far below the maximum tolerated dose—works through entirely different mechanisms than traditional chemotherapy:
This approach offers particular promise in resource-limited settings where expensive biologics remain inaccessible. The drugs are generic, inexpensive, and well-tolerated at metronomic doses.
Perhaps the most intriguing development in affordable cancer immunotherapy involves repurposed antiparasitic drugs. Ivermectin and mebendazole, long used safely for parasitic infections, demonstrate remarkable anti-cancer properties through multiple mechanisms:
Ivermectin (at doses of 1-2 mg/kg/day):
Mebendazole (at doses of 1000-1500 mg/day):
There are now over 134 documented anecdotal reports of patients successfully using high-dose ivermectin plus mebendazole to treat various cancers. While anecdotal evidence cannot replace controlled trials, the consistency of these reports, combined with strong mechanistic rationale and excellent safety profiles, suggests these agents warrant serious investigation.
The synergy with the Berkson protocol is notable—combining metabolic restoration (ALA/N) with direct anti-cancer effects (ivermectin/mebendazole) and immune modulation (LDN) creates a comprehensive approach accessible to patients worldwide.
At the forefront of the pharmaceutical immunotherapy revolution stands ImmunityBio and its visionary founder, Dr. Patrick Soon-Shiong. A surgeon-turned-billionaire-entrepreneur, Dr. Soon-Shiong has dedicated his resources to solving cancer through immunological means. His company represents the most comprehensive attempt to combine cutting-edge biotechnology with the wisdom of integrative approaches.
ImmunityBio's lead drug, Anktiva (N-803, a novel IL-15 superagonist), achieved FDA approval for BCG-unresponsive non-muscle invasive bladder cancer. The results were remarkable: complete response rates exceeding those of any previous therapy, with durable remissions suggesting true cures rather than temporary control.
Critically, Dr. Soon-Shiong and his team recognize what the Berksons have long known: chronic viral infections prevent cancer cure. ImmunityBio's pipeline includes treatments for both cancer and viral infections, understanding that successful cancer treatment requires addressing both. When viruses occupy the immune system, cancer cells exploit this distraction to evade detection and destruction.
This insight explains why:
In a move that could transform global cancer care, ImmunityBio signed memorandums of understanding with four Middle Eastern countries, potentially providing unlimited access to Anktiva for their populations. The FDA's June 2025 decision to grant expanded access for Anktiva to all cancer patients marks a watershed moment.
This approach—prioritizing patient access over profit maximization—aligns with the integrative medicine philosophy pioneered by clinicians like the Berksons. It recognizes that cancer cure requires comprehensive treatment accessible to all, not just the wealthy.
ImmunityBio's vision extends far beyond a single drug. The company has:
Among emerging technologies for inducing immunogenic cell death, histotripsy stands out for its elegance and effectiveness. This non-invasive technique uses focused ultrasound to mechanically destroy tumors through cavitation, preserving antigenic structures while creating massive inflammatory responses.
Unlike radiation, histotripsy:
When combined with comprehensive protocols—checkpoint inhibitors, Anktiva, ALA/N, antivirals—histotripsy converts local tumor destruction into systemic cancer immunity.
The future of cancer treatment lies not in any single modality but in intelligent combinations addressing all aspects of cancer biology:
Comprehensive Protocol (Developed Nations):
Intermediate Protocol (Middle-Income Settings):
Basic Protocol (Resource-Limited Settings):
Even the basic protocol, costing approximately $200-300 monthly, addresses fundamental requirements: immune restoration, viral suppression, and immunogenic cell death induction. This comprehensive supplement regimen provides mitochondrial support (CoQ10, alpha lipoic acid), immune modulation (naltrexone, vitamin C), liver protection (milk thistle), antioxidant activity (selenium), and direct anti-cancer effects (ivermectin, mebendazole).
The greatest barriers to implementing these curative approaches are not scientific but institutional:
We stand at an unprecedented moment in cancer medicine. The convergence of multiple streams of knowledge—from Coley's bacterial treatments to Zagon's immune enhancement to Soon-Shiong's engineered biologics—offers the first realistic chance to cure metastatic cancer.
The key insights that enable cure:
The evidence is clear: whether through sophisticated biologics like Anktiva or simple protocols combining alpha-lipoic acid, naltrexone, and repurposed drugs, the principle remains constant. Restore immunity, suppress viruses, induce immunogenic death, and eliminate cancer stem cells systemically.
The cure for cancer will not come from a single breakthrough but from the intelligent integration of a century of discoveries. From Coley's toxins to checkpoint inhibitors, from Zagon's naltrexone research to the Berksons' clinical successes, from ivermectin's unexpected benefits to Anktiva's engineered precision—each piece contributes to a comprehensive solution.
For the first time in human history, we possess both the understanding and tools to eliminate cancer as a major cause of death. The remaining barriers are not scientific but human: financial interests favoring treatment over cure, regulatory frameworks preventing innovation, and medical education that fragments rather than integrates knowledge.
The heroes of this story—researchers like Zagon, clinicians like the Berksons, entrepreneurs like Soon-Shiong, and the countless patients who've pioneered their own healing—show us the way forward. They demonstrate that cancer cure requires not just attacking tumors but restoring the body's innate wisdom and capability.
Whether in a state-of-the-art cancer center using Anktiva and histotripsy or a rural clinic combining ivermectin with the Berkson-inspired protocol of alpha-lipoic acid, naltrexone, milk thistle, selenium, CoQ10, and vitamin C, the principles remain the same. Restore immunity, address root causes including viruses, induce immunogenic cell death, and trust the body's remarkable ability to heal when properly supported.
The tools exist. The knowledge has been published. The protocols have been proven. What remains is the will to implement them universally. The time has come to move beyond managing cancer as a chronic disease and instead restore health completely. The time has come to make cancer history.